Publications and Presentations
08/20/20 – Newsletter
Brenda M. Maloney Shafer AstraZeneca to Cut Off 340B Pricing for Contract Pharmacies on October 1 Health & Life Sciences Alert Brenda M. Maloney Shafer, Richard B. DavisAs reported by 340B Health on August 18, 2020, drug manufacturer AstraZeneca has sent this letter to covered entities indicating that it will cease providing 340B pricing for 340B-eligible drugs dispensed by contract pharmacies on October 1, 2020.
AstraZeneca has explained... Read More
07/10/20 – Newsletter
Notice to Covered Entities: Manufacturer Seeking 340B Claims Data To Be or Not to 340B Blog Brenda M. Maloney Shafer, Richard B. Davis
05/20/20 – Presentation
"Multistate Pharmacy Jurisprudence Review" Medical College of Wisconsin School of Pharmacy By: Roger N. Morris, Richard B. Davis
04/30/20 – Newsletter
CMS Publishes 340B Drug Acquisition Cost Survey: Respond by May 15, 2020 To Be or Not to 340B Blog Brenda M. Maloney Shafer, Richard B. Davis
03/23/20 – Newsletter
HRSA Unveils New 340B Flexibilities During COVID-19 Crisis To Be or Not to 340B Blog Brenda M. Maloney Shafer, Richard B. Davis
02/03/20 – Newsletter
GAO Report Suggests Increased Oversight of 340B Program To Be or Not to 340B Blog Brenda M. Maloney Shafer, Richard B. Davis
01/14/20 – Newsletter
The Latest on Proposed Changes to Wisconsin Patient Counseling Rule That Will Impact Mail Order Pharmacies: Board Submits Final Rule Draft Health & Life Sciences Alert Susan B. Trujillo, Richard B. Davis, Christopher M. Guthrie
11/25/19 – Newsletter
Board’s Economic Impact Analysis Disputes Industry Submissions, Board Advances Proposed Rule Without Changes Health & Life Sciences Alert Susan B. Trujillo, Richard B. Davis
11/19/19 – Newsletter
Results of Economic Impact Discussion: The Latest on Proposed Changes to Wisconsin Patient Counseling Rule That Will Impact Mail Order Pharmacies Health & Life Sciences Alert Susan B. Trujillo, Richard B. Davis
11/05/19 – Newsletter
The Latest on Proposed Changes to Wisconsin Patient Counseling Rule That Will Impact Mail Order Pharmacies: Potential Relief for Mail Order Pharmacies? Health & Life Sciences Alert Susan B. Trujillo, Richard B. Davis
10/30/19 – Newsletter
The Latest on Proposed Changes to Wisconsin Patient Counseling Rule That Will Impact Mail Order Pharmacies Health & Life Sciences Alert Susan B. Trujillo, Richard B. Davis
10/25/19 – Newsletter
Update on Status of Proposed Wisconsin Patient Counseling Rule that Will Impact Mail Order Pharmacies Health & Life Sciences Alert Susan B. Trujillo, Richard B. Davis
10/14/19 – Newsletter
Applications Now Available for Alaska's New Licensing Categories and Prescription Standards Health & Life Sciences Alert Susan B. Trujillo, Nicholas H. Meza, Richard B. Davis
09/18/19 – Newsletter
New PBM State Laws Indicate a Shifting Battlefront over 340B Program Drug Pricing To Be or to Not to 340B Blog Brenda M. Shafer, Richard B. Davis
08/06/19 – Newsletter
Interesting 340B Takeaways from 2020 OPPS Proposed Rule To Be or Not to 340B Blog Brenda M. Maloney Shafer, Richard B. Davis, Benjamin A. Lockwood
08/01/19 – Newsletter
503B Loses Federal Preemption Argument, Appeals to Ninth Circuit Health & Life Sciences Alert Susan B. Trujillo, Richard B. Davis, Benjamin A. Lockwood
07/18/19
"The 340B Drug Pricing Program Year in Review: What's Smoke and What's Fire in a Changing Landscape" Quarles & Brady Pharmacy Law Symposium
07/09/19 – Blog
340B Litigation Updates and Other Program Developments To Be or Not to 340B Brenda M. Shafer, Richard B. Davis
03/19/19 – Newsletter
The President’s 2020 Budget Keeps 340B Program in the Spotlight To Be or Not to 340B Brenda Maloney Shafer, Richard Davis
02/25/19 – Blog
"CVS Caremark Reverses Planned Payment Cuts to 340B Providers" To Be or Not to 340B Brenda M. Shafer, Richard B. Davis
01/29/19 – Blog
"We're 340Back! Review of Major Developments to the 340B Program" To Be or Not to 340B Brenda M. Shafer and Richard B. Davis
Brenda M. Maloney Shafer
